Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Combemale, Patrick ^a   Valeyrie Allanore, Laurence ^b   Giammarile, Francesco ^a   Pinson, Stephane ^a   Guillot, Bernard ^c   Goulart, Denis Mariano ^c   Wolkenstein, Pierre ^b   Blay, Jean Yves ^a   Mognetti, Thomas ^a  

^a CENTRE LÉON BÉRARD   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MULTICENTER STUDY; NEGATIVE LIKELIHOOD RATIO; NEUROFIBROMATOSIS; ONCOLOGICAL PARAMETERS; POSITIVE LIKELIHOOD RATIO; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SENSIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TUMOR AND THE NORMAL LIVER RATIO; TUMOR CLASSIFICATION; CELL TRANSFORMATION; CLINICAL TRIAL; COMPLICATION; DEMOGRAPHY; DIAGNOSTIC USE; LIVER; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; SARCOMA; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; DEMOGRAPHY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY; SARCOMA;

EID: 84895541256     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085954     Document Type: Article

References (51)

1. Pinson S, Creange A, Barbarot S, Stalder JF, Chaix Y, et al. (2001) Neurofibromatosis 1: recommendations for management. Ann Dermatol Vénéréol 128: 567-575.
2. Evans DG, Baser ME, Mc Gaughran J, Sharif S, Howard E, et al. (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39: 311-314. (Pubitemid 34526349)
3. Rasmussen SA, Yang Q, Friedman JM. (2010) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68: 1110-1118.
4. Doorn PF, Molenaar WM, Buter J, Hoekstra HJ. (1995) Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol 21: 78-82.
5. Ferner RE, Gutmann DH. (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62: 1573-1577. (Pubitemid 34407825)
6. Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, et al. (2004) The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30: 83-101. (Pubitemid 38240089)
7. Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, et al. (2013) Variance of SUVs for FDG-PET/CT is greater in clinical practice than Under idéal study settings. Clin Nucl méd 38: 175-182.
8. De Langen AJ, Vincent A, Velasquez LM, Van Tinteren HT, Boellaard R, et al. (2012) Repeatability of 18 F-FDG uptake measurements in tumors :a metaanalysis. J Nucl Med 53: 701-708.
9. Tessonnier L, Sebag F, Palazzo FF, Colavolpe C, De Micco C, et al. (2008) Does (18)-FDG PET/CT add diagnostic accuracy in incidentally identified non secreting adrenal tumors? Eur J Nucl Med Mol Imaging 35: 2018-2025.
10. Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, et al. (2009) Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesion. Ann Nucl Med 23: 349-354.
11. Neurofibromatosis. Conference statement. (1998) National Institutes of Health Consensus Development Conference. Arch Neurol 45: 575-578.
12. Bensaid B, Giammarile F, Mognetti T, galoisy-Guibal L, Pinson S, et al. (2007) Intérêt de la scintigraphie au FDG 18 dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1 Ann Dermatol Vénéréol 134: 735-742.
13. Valeyrie-Allanore L, Ismaili N, Bastuji-Garin S, Zeller J, Wechsler J, et al. (2005) Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1. Br J Dermatol 153: 79-82. (Pubitemid 41044531)
14. Mantaka P, Strauss AD, Strauss LG, Moehler M, Goldschmidt H, et al. (1999) Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET). Anticancer Res 19: 4443-4450. (Pubitemid 30042804)
15. Wick MR, Swanson PE, Scheithauer BW, Manivel JC. (1987) Malignant peripheral nerve sheath tumor. An immunohistochemical study of 62 cases. Am J Clin Pathol 87: 425-433. (Pubitemid 17050214)
16. Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT et al. (2012) Malignant peripheral Nerve Sheath tumors (MPNST): The Mayo clinic experience. Ann Surg Oncol 19: 878-885.
17. King AA, Debaun MR, Riccardi VM, Gutmann DH. (2000) Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 93: 388-392. (Pubitemid 30622184)
18. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57: 2006-2021. (Pubitemid 16113778)
19. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. (1999) Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65: 205-211.
20. Ramanathan RC, Thomas JM. (1999) Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis. Eur J Surg Oncol 25: 190-193. (Pubitemid 29182463)
21. Woodruff JM. (1999) Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet 89: 23-30.
22. Loree TR, North JH Jr, Werness BA, Nangia R, Mullins AP, et al. (2000) Malignant peripheral nerve sheath tumors of the head and neck: analysis of prognostic factors. Otolaryngol Head Neck Surg 122: 667-672. (Pubitemid 30333842)
23. Porter DE, Prasad V, Foster L, Dall GF, Birch R, et al. (2009) Survival in Malignant Peripheral Nerve Sheath Tumours: a comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma 2009: 756395.
24. Le Pechoux C, Pautier P, Delannes M, Bui BN, Bonichon F, et al. (2006) Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma. Cancer Radiother 10: 185-207.
25. Demas BE, Heelan RT, Lane J, Marcove R, Hajdu S, et al. (1988) Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 150: 615-620. (Pubitemid 18075406)
26. De Schepper AM, Ramon FA, Degryse HR. (1992) Magnetic resonance imaging of soft tissue tumors. J Belge Radiol 75: 286-296.
27. Van Herendael BH, Heyman SR, Vanhoenacker FM, De Temmerman G, Bloem JL, et al. (2006) The value of magnetic resonance imaging in the differentiation between malignant peripheral nerve-sheath tumors and non-neurogenic malignant soft-tissue tumors. Skeletal Radiol 35: 745-753. (Pubitemid 44317527)
28. Banks KP. (2005) The target sign: extremity. Radiology 234: 899-900. (Pubitemid 40250835)
29. Crim JR, Seeger LL, Yao L, Chandnani V, Eckardt JJ. (1992) Diagnosis of soft-tissue masses with MR imaging: can benign masses be differentiated from malignant ones? Radiology 185: 581-586.
30. Knight SB, Delbeke D, Stewart JR, Sandler MP. (1996) Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 109: 982-988. (Pubitemid 26113641)
31. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. (1994) Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 35: 1771-1776. (Pubitemid 24346796)
32. Schmidt M, Schmalenbach M, Jungehulsing M, Theissen P, Dietlein M, et al. (2004) 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis. Nuklearmedizin 43: 91-104.
33. Cheng D, Alavi A, Lim E, Werner T, Del Bello CV. (2013) Dynamic changes of FDG Uptake and clearance in normal tissues. Mol Imaging Biol 15: 345-352.
34. Frohlich A, Diederichs CG, Staib L, Vogel J, Beger HG, et al. (1999) Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 40: 250-255. (Pubitemid 29077086)
35. Hubner KF, Buonocore E, Gould HR, Thie J, Smith GT, et al. (1996) Differentiating benign from malignant lung lesions using " quantitative" parameters of FDG PET images. Clin Nucl Med 21: 941-949. (Pubitemid 26412217)
36. Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ. (2009) [18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36: 751-757.
37. Miyamoto J, Tatsuzawa K, Owada K, Kawabe T, Sasjima H, et al. (2008) Usefulness and limitations of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for detection of malignancy of orbital tumors. Neurol Med Chir (Tokyo) 48: 495-499.
38. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, et al. (2010) Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 116: 451-458.
39. Otsuka H, Graham MM, Kubo A, Nishitani H. (2005) FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report. Ann Nucl Med 19: 55-58. (Pubitemid 40410289)
40. Santaella Y, Borrego I, Lopez J, Ortiz MJ, Vazquez R. (2005) 18-FDG-PET in a case of recurrent malignant schwannoma. Rev Esp Med Nucl 24: 127-130. (Pubitemid 40463747)
41. Chander S, Westphal SM, Zak IT, Bloom DA, Zingas AP, et al. (2004) Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med 29: 415-418. (Pubitemid 38780609)
42. Solomon SB, Semih Dogan A, Nicol TL, Campbell JN, Pomper MG. (2001) Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis. Clin Nucl Med 26: 525-528. (Pubitemid 32429246)
43. Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, et al. (2003) Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29: 536-541. (Pubitemid 37009972)
44. Brenner W, Friedrich RE, Gawad KA, et al. (2006) Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 33: 428-432.
45. Tsai LI, Drubach L, Fahey F' Irons M, Voss S, Ulrich NJ. (2012) (18)-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with mailgnant transformation. J Neurooncol 108: 469-475.
46. Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A. (2009) Potential role of (18)-Fluorodeoxyglucose positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery 65: A160-A170.
47. Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, et al. (2000) Evaluation of (18) fluorodeoxyglucose positron emission tomography ((18) FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.J Neurol Neurosurg Psychiatry 68: 353-357. (Pubitemid 30248712)
48. Ferner RE, Golding JF, Smith M, Calonje E, Jan W, et al. (2008) (18F) 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 19: 390-394. (Pubitemid 351201726)
49. Laffon E, Adhoute X, de Clermont H, Marthan R. (2011) Is liver stable over time in 18 F-FDG PET imaging. J Nucl Med Technol 39: 258-263.
50. Shahid KR, Amrami KK, Esther RJ, Lowe VJ, Spinner RJ. (2011) False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of a neurofibromatosis type 1. J Surg Orthop Adv 20: 132-135.
51. Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, et al. (2013) 18-Fluorodeoxyglucose positron emission tomography FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer 60: 59-64.